Library — CHDR

Search

Filter

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R

Journal of psychopharmacology (Oxford, England), 2018 Dec; 32(6):668-677

View publication
The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF

Journal of psychopharmacology (Oxford, England), 2018 Dec; 13(1):10-7

View publication
Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep.

Tuk B, Oberyé JJ, Pieters MS, Schoemaker RC, Kemp B, van Gerven J, Danhof M, Kamphuisen HA, Cohen AF, Breimer DD, Peck CC

Clinical pharmacology and therapeutics, 2018 Dec; 62(4):444-52

View publication
Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in the first-in-human study.

Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J

Clinical pharmacology and therapeutics, 2018 May

View publication
The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JM, Hay JL

Clinical pharmacology in drug development, 2015 Feb; 4(2):149-54

View publication
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.

Hoch M, van Gorsel H, van Gerven J, Dingemanse J

Journal of clinical pharmacology, 2014 Aug; 54(9):979-86

View publication
Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.

Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J

Journal of clinical psychopharmacology, 2013 May; 33(3):363-70

View publication
Guidelines for the recording and evaluation of pharmaco-sleep studies in man: the International Pharmaco-EEG Society (IPEG).

Jobert M, Wilson FJ, Roth T, Ruigt GS, Anderer P, Drinkenburg WH, Bes FW, Brunovsky M, Danker-Hopfe H, Freeman J, van Gerven JM, Gruber G, Kemp B, Klösch G, Ma J, Penzel T, Peterson BT, Schulz H, Staner L, Saletu B, Svetnik V,

Neuropsychobiology, 2013 Mar; 67(3):127-67

View publication
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013 Jan; 23(2):107-17

View publication

«
1
2
»